Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues

Executive Summary

AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.

Related Content

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Preparing Emerging Biotechs For The Best Deals – Insider Insights
Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition
Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer
In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies
Manufacturing Compliance Updates In Brief: Dasan, Akorn, Evertogen And 10 Others
And Then There Were Five: Roche's Tecentriq Joins Europe I-O Race
Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer
Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts